Brii Biosciences Reports Promising Phase 2 Results for HBV Treatment

The latest update is out from Brii Biosciences Limited ( (HK:2137) ).

Brii Biosciences Limited announced promising interim data from its Phase 2 ENSURE study, presented at the European Association for the Study of the Liver Congress 2025. The study evaluates the combination of elebsiran, an investigational siRNA, with pegylated interferon alpha (PEG-IFN α) in treating chronic hepatitis B virus (HBV) infection. Results showed that participants previously treated with BRII-179, a therapeutic vaccine, achieved faster and higher rates of hepatitis B surface antigen (HBsAg) seroclearance compared to those without prior treatment. This suggests that pre-treatment with BRII-179 may enhance immune response, potentially allowing for shorter treatment durations. The findings could significantly impact the treatment landscape for chronic HBV, offering a more effective and efficient therapeutic option for patients.

More about Brii Biosciences Limited

Brii Biosciences Limited is a biotechnology company focused on developing innovative therapies for infectious diseases, particularly chronic hepatitis B virus (HBV) infection. The company leverages advanced technologies such as small interfering ribonucleic acid (siRNA) and recombinant protein-based vaccines to enhance treatment outcomes.

Average Trading Volume: 8,054,275

Technical Sentiment Signal: Buy

Current Market Cap: HK$1.52B

See more data about 2137 stock on TipRanks’ Stock Analysis page.